Ranbaxy acquires French generic company RPG Aventis
Ranbaxy Laboratory, India's largest pharmaceutical company, has bagged the French generic drug company RPG Aventis for about $70m.
Ranbaxy Laboratory, India's largest pharmaceutical company, has bagged the French generic drug company RPG Aventis for about $70m.
The company out-bid several European companies and another Indian company. The RPG Aventis deal is one of the largest cross-border acquisitions by an Indian pharmaceutical company.
The takeover will not only give Ranbaxy a healthy share in the European generics market, but will also enhance its position as a global generics player. Europe is currently the fastest growing market for Ranbaxy though at present it accounts for less than 15% of the company's global sales.
RPG Aventis is one of the leading generic producers in France, and recorded sales of some €48m in 2002. The company has a portfolio of more than 100 generic products with a significant presence across most of the therapeutic segments including cardiovascular, analgesics, dermatology, gastro-enterology, anti-infectives and psychiatry.